Inhibitor of anandamide uptake (IC50 = 17.3 μM) with little or no activity at CB1, CB2, TRPV1 and FAAH. Intravenous administration inhibits limb spasticity in mice with chronic relapsing experimental allergic encephalomyelitis (CREAE).
Sold under license from VCU-IPF
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble in ethanol (supplied pre-dissolved in anhydrous ethanol, 5mg/ml)|
Preparing Stock Solutions
The following data is based on the product molecular weight 584.62. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.71 mL||8.55 mL||17.11 mL|
|5 mM||0.34 mL||1.71 mL||3.42 mL|
|10 mM||0.17 mL||0.86 mL||1.71 mL|
|50 mM||0.03 mL||0.17 mL||0.34 mL|
References are publications that support the products' biological activity.
Di Marzo et al (2002) A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J.Pharmacol.Exp.Ther. 300 984 PMID: 11861807
Ligresti et al (2006) New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br.J.Pharmacol. 147 83 PMID: 16284631
If you know of a relevant reference for O-2093, please let us know.
View Related Products by Product Action
Keywords: O-2093, supplier, inhibitors, inhibits, anandamide, reuptake, AMT, Transporters, Cannabinoids, Monoamine, Neurotransmitter, Cannabinoid, Transporters, Cannabinoid, Transporters, Tocris Bioscience
Citations for O-2093
Citations are publications that use Tocris products.
Currently there are no citations for O-2093. Do you know of a great paper that uses O-2093 from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)